Radionuclide Selection Influences Imaging Outcomes in Immuno-PET with a Brain-Penetrating Anti-Amyloid-β Antibody. [PDF]
J Nucl MedLopes van den Broek S +5 more
europepmc +1 more source
Detection of inflammation-related blood-brain barrier dysfunction using PET and MR imaging: a pilot study. [PDF]
Sci RepHilbrig CF +7 more
europepmc +1 more source
The impact of weakly bound 89Zr on preclinical studies: Non-specific accumulation in solid tumors and aspergillus infection [PDF]
, 2015 Hansen, Anders Elias +9 more
core +1 more source
Anti-cancer immune priming with β-radioligand therapy using a novel high affinity antibody selectively targeting the 4Ig-Isoform of B7-H3. [PDF]
TheranosticsGlazer SE +6 more
europepmc +1 more source
Pilot study of Zr-bevacizumab positron emission tomography in patients with advanced non-small cell lung cancer [PDF]
core +1 more source
PET-CT Imaging in Breast Cancer Patients: New Tracers, Future Directions [PDF]
, 2013 Dank, Magdolna +5 more
core +1 more source
Dosimetry and first human experience with 89Zr-panitumumab.
American journal of nuclear medicine and molecular imaging89Zr-panitumumab is a novel immuno-PET radiotracer. A fully humanized IgG2 antibody, panitumumab binds with high affinity to the extracellular ligand binding domain of EGFR. Immuno-PET with radiolabeled panitumumab is a non-invasive method that could characterize EGFR expression in tumors and metastatic lesions.
Liza, Lindenberg +10 more
openaire +1 more source
Molecular imaging of tucatinib-induced cellular and TME changes in preclinical models of HER2 + breast cancer. [PDF]
Breast Cancer Res TreatSong PN +5 more
europepmc +1 more source
<i>In Vivo</i> Evaluation of a Self-Excitatory Near-Infrared ImmunoSCIFI Probe. [PDF]
Bioconjug ChemGristwood K +4 more
europepmc +1 more source
Claudin 18.2 as a Biomarker for Imaging and Radiopharmaceutical Therapy in Gastric and Pancreatic Tumors. [PDF]
J Nucl MedRaheem SJ +10 more
europepmc +1 more source